Hemostasis is a complex system composed of many procoagulant and regulatory pathways. Multiple pathways, such as the intrinsic pathway, platelet activation and the tissue factor pathway, can affect ...

The coagulation cascade is a finely balanced system essential for maintaining haemostasis, yet its disruption can lead to either a propensity for bleeding or an increased risk of clot formation.

As people age they become more prone to blood clotting diseases, which can be caused when blood platelets clump together. This clumping can lead to strokes and cardiovascular disease. For decades, ...

Blood clotting can lead to life-threatening heart attacks and strokes, and current treatments can lead to excessive bleeding and other worrisome side effects. But researchers now say they've found a ...

February 6, 2007 (Seattle, WA) - Variants in key coagulation and anticoagulation proteins were more common in postmenopausal women who developed venous thrombosis (VT) than in those who did not, ...

Studies by researchers at Columbia University Irving Medical Center suggest that one of the immune system’s oldest branches, the complement system, and coagulation dysfunction, may be influencing the ...

Researchers have discovered the blood clotting and immune protein pathways that are activated in severe cases of COVID-19 in children, paving the way for earlier diagnosis and more targeted treatments ...

Hemophilia A and B involve deficiencies in coagulation factors VIII and IX, with traditional treatments requiring frequent infusions. Nonfactor therapies, including Hemlibra and rebalancing agents, ...

Inflammatory bowel disease, in which the immune system attacks the gut, is a painful chronic condition that affects three million Americans. Rates of IBD are rising, and there's currently no cure. IBD ...

A DZHK research team at the University Medical Center Mainz has discovered a new signaling pathway of the coagulation system that controls scar formation after a heart attack. If this signaling ...

A novel class of antithrombotic medication, the factor XIa inhibitors, has had a rocky start but is powering through phase III trials, which are now underway. MedPage Today sat down to discuss the ...